Premium
New treatments in ulcer healing and wound infection
Author(s) -
Edmonds M.,
Bates M.,
Doxford M.,
Gough A.,
Foster A.
Publication year - 2000
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/1520-7560(200009/10)16:1+<::aid-dmrr142>3.0.co;2-s
Subject(s) - medicine , filgrastim , hyaluronic acid , diabetic foot ulcer , wound care , wound healing , granulocyte colony stimulating factor , clinical trial , diabetic foot , surgery , intensive care medicine , diabetes mellitus , chemotherapy , anatomy , endocrinology
This review examines several of the recently introduced wound care products that have been put forward as treatment modalities for the diabetic foot ulcer. Discussed are the results of clinical trials with the platelet‐derived growth factor, becaplermin, the tissue‐engineered products Dermagraft and Apligraf, and Hyaff which is an ester of hyaluronic acid. In patients with an infected foot ulcer, encouraging results were obtained with the granulocyte‐colony stimulating factor, Filgrastim. Copyright © 2000 John Wiley & Sons, Ltd.